Amicus Therapeutics, Inc.

As of December 31, 2025, Amicus Therapeutics, Inc. has 310.85M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 6.92, and the price-to-book ratio stands at -1.59.

As of December 31, 2025, Amicus Therapeutics, Inc. trades at an EV/EBITDA multiple of 108.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 131.53 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Amicus Therapeutics, Inc. trades at an EV/FCF ratio of 702.09, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2025, Amicus Therapeutics, Inc. maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 161.30, indicating elevated leverage, while an interest coverage ratio of 0.91 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on invested capital (ROIC) is negative at -698.76, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -3.13, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 285.07, useful for judging operating efficiency across full business cycles. Inventory turnover of 0.42 indicates how many times Amicus Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended December 31, 2025. That works out to an effective tax rate of 14,293.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended December 31, 2025, Amicus Therapeutics, Inc. posted a gross margin of 88.50, reflecting its pricing power and cost economics. The operating margin of 5.44 and net profit margin of -4.27 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 0.75, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.01, meaning Amicus Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Amicus Therapeutics, Inc. has an Altman Z-Score of 0.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.